StreetAlpha.app
Home › Stocks › TCRX

TScan Therapeutics, Inc. (TCRX)

$0.15
▲ +4.07%
LAST CLOSE · NOV 17

TScan Therapeutics develops engineered T cell therapies, including TCR-T product candidates that are still in clinical development. It last closed at $0.15 on Nov 17, up 4.07% on the day. The average 12-month price target from 2 analysts is $1.00 (+562.3% from the last close), with a high of $1.00 and a low of $1.00.

AI Auto Pilots
Is TCRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$5.2M
−38.4% vs a year ago
Net income
−$115.1M
−2219.2% margin
EPS (diluted)
−$0.89
Free cash flow
−$111.7M
−2153.3% margin
Balance sheet
Cash & equivalents
$73.0M
At Sep 30
Debt
$33.0M
At Sep 30
Shareholder equity
$38.0M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $10.1M$10.1MFY2021FY2022: $13.5M$13.5MFY2022FY2023: $21.0M$21.0MFY2023FY2024: $2.8M$2.8MFY2024FY2025: $10.3M$10.3MFY2025

From TCRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Hold
2firms
0 Buy2 Hold0 Sell
Only 2 firms rated TCRX in the past 90 days, not enough for a consensus
Average 12-month target
$1.00
▲ 562.3% upside

Based on 2 analysts who set a price target on TCRX in the past 90 days. The average target is $1.00, with a high of $1.00 and a low of $1.00, compared with the last close of $0.15.

Low $1.00Avg $1.00High $1.00
Blue marker: last close $0.15
Highest target$1.00
Average target$1.00
Lowest target$1.00
Latest rating changes
HC Wainwright & Co.Downgrade
Sep 8Hold$7 → $1
WedbushDowngrade
Sep 3Hold$5 → $1
HC Wainwright & Co.Reiterated
Aug 12Buy$7
WedbushReiterated
Jun 23Buy$5
NeedhamReiterated
Jun 23Buy$6
DateFirmActionRatingPrice target
Sep 8HC Wainwright & Co.DowngradeHold$7 → $1
Sep 3WedbushDowngradeHold$5 → $1
Aug 12HC Wainwright & Co.ReiteratedBuy$7
Jun 23WedbushReiteratedBuy$5
Jun 23NeedhamReiteratedBuy$6
Loading…

Technical Analysis

TCRX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 23% below its 20 day and 66% below its 50 day average. It is 427% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the Pivot at $0.15, and the nearest resistance the Pivot R1 at $0.16.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 14.0%/day
Key levels
$1.4752 week high+880.0%
$0.80200 day average+433.3%
$0.53100 day average+253.3%
$0.2550 day average+66.7%
$0.21Swing high (Nov 4)+40.0%
$0.1920 day average+26.7%
$0.16Pivot R1+6.7%
$0.15Pivot+0.0%
$0.15Last close
$0.1452 week low−6.7%
$0.14Pivot S1−6.7%
Indicators
RSI (14)30.77Weak, oversold below 30Neutral
MACD-0.03Below its signal lineBearish
Stochastic4.5Near the bottom of its rangeOversold
ADX (14)50.1Strong downtrend
Williams %R-87.2Oversold below −80, overbought above −20Oversold
CCI (20)-189.8Oversold below −100, overbought above 100Oversold
Rate of change−20.1%Change over 10 sessionsBearish
ATR (14)$0.02Typical daily range, 14.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TCRX

What happened before

See how TCRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TCRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TCRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in TCRX in the last 90 days.

Loading…

See today’s whale options flow across the market →

TCRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼14 buying vs 35 selling
  • ▼Shares held by funds -9.8%
  • ▼Funds holding -8
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding5260−13.3%
In funds' top 1023−33.3%
Held by funds–––
New / increased6 / 86 / 23−51.7%
Reduced / sold out22 / 1312 / 7+84.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TCRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TCRX is in one of them and how their past TCRX trades turned out.

TCRX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TCRX in an article yet. Here's the latest on the wider market.

About TScan Therapeutics

TScan Therapeutics is a biological products company based in Waltham, Massachusetts, that develops engineered T cell therapies. Its main focus is a set of TCR-T therapy product candidates, which are still in development and are being studied in clinical trials. These candidates are meant for physicians and the patients they treat, and the company must manufacture them and win regulatory approval before they can be sold. The company relies on contract research organizations, clinical sites and outside manufacturers to carry out its work.

Headquarters
Waltham, MA